- Home
- SCLX vs FGEN Comparison
SCLX vs FGEN Comparison
Compare SCLX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- FGEN
- Stock Information
- Founded
- SCLX 2011
- FGEN 1993
- Country
- SCLX United States
- FGEN United States
- Employees
- SCLX N/A
- FGEN N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SCLX Health Care
- FGEN Health Care
- Exchange
- SCLX Nasdaq
- FGEN Nasdaq
- Market Cap
- SCLX 33.9M
- FGEN 33.5M
- IPO Year
- SCLX N/A
- FGEN 2014
- Fundamental
- Price
- SCLX $6.38
- FGEN $5.85
- Analyst Decision
- SCLX Strong Buy
- FGEN Strong Buy
- Analyst Count
- SCLX 3
- FGEN 1
- Target Price
- SCLX $367.50
- FGEN $250.00
- AVG Volume (30 Days)
- SCLX 96.4K
- FGEN 60.4K
- Earning Date
- SCLX 08-12-2025
- FGEN 08-05-2025
- Dividend Yield
- SCLX N/A
- FGEN N/A
- EPS Growth
- SCLX N/A
- FGEN N/A
- EPS
- SCLX N/A
- FGEN N/A
- Revenue
- SCLX $50,710,000.00
- FGEN $6,996,000.00
- Revenue This Year
- SCLX $107.00
- FGEN N/A
- Revenue Next Year
- SCLX $82.52
- FGEN N/A
- P/E Ratio
- SCLX N/A
- FGEN N/A
- Revenue Growth
- SCLX 7.79
- FGEN N/A
- 52 Week Low
- SCLX $3.60
- FGEN $4.50
- 52 Week High
- SCLX $73.50
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- SCLX 60.64
- FGEN 43.29
- Support Level
- SCLX $6.00
- FGEN $5.37
- Resistance Level
- SCLX $6.76
- FGEN $5.73
- Average True Range (ATR)
- SCLX 0.42
- FGEN 0.41
- MACD
- SCLX 0.11
- FGEN 0.07
- Stochastic Oscillator
- SCLX 82.06
- FGEN 77.78
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.